ActivX is an emerging biopharmaceutical company that discovers and develops highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX uses its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with an initial focus on the areas of hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.
The KiNativ™ platform provides an unrivaled ability to quantitatively profile kinase inhibitors against native kinases in virtually any cell or tissue lysate, including those derived from in vivo animal studies. This chemoproteomics technology assays kinase inhibition directly in biological samples where protein-protein interactions, differential phosphorylation, and other naturally occurring modifications are preserved. The ActivX universal kinase probes allow for a cross-species platform that supports kinase inhibitor characterization throughout the drug discovery process. Specific applications include the evaluation of inhibitor potency and specificity, target identification, hit validation, and hit-to-lead optimization. Moreover, the unique ability to directly assess target engagement in pre-clinical and clinical samples affords unparalleled potential to expedite drug development.
"Data delivery timeline was met on time and ordering process was smooth. However, at times Tyzoon Nomanbhoy's responses to questions/comments can be very abrupt and damaging to the company-customer relationship."
ActivX Biosciences, Inc has not received any endorsements.